Evidence map›Paper›PMID 39593042›Full record

Observational studyPediatric rheumatology online journal2024

Real-world psychosocial impact among patients with juvenile idiopathic arthritis and families in Spain.

Inmaculada Calvo Penadés, Estefania Moreno Ruzafa, Joan Calzada-Hernández, Juan Mosquera Angarita, Berta López Montesinos, Rosa Bou, Mireia López Corbeto, Judith Sánchez-Manubens, María Isabel González Fernández, Sonia Carriquí Arenas and 12 more

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Pediatric rheumatology online journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Inmaculada Calvo PenadésPediatric Rheumatology Unit. Hospital Universitario y Policlínico La Fe, La Fe Health Research Institute, Valencia, Spain.
Estefania Moreno RuzafaPediatric Rheumatology Section, Hospital Campus Universitari Vall d'Hebron, Barcelona, Spain.
Joan Calzada-HernándezPediatric Rheumatology Department, Hospital San Joan de Déu, Barcelona, Spain.
Juan Mosquera AngaritaPediatric Rheumatology Department, Hospital San Joan de Déu, Barcelona, Spain.
Berta López MontesinosPediatric Rheumatology Unit. Hospital Universitario y Policlínico La Fe, La Fe Health Research Institute, Valencia, Spain.
Rosa BouPediatric Rheumatology Department, Hospital San Joan de Déu, Barcelona, Spain.
Mireia López CorbetoPediatric Rheumatology Section, Hospital Campus Universitari Vall d'Hebron, Barcelona, Spain.
Judith Sánchez-ManubensPediatric Rheumatology Department, Hospital San Joan de Déu, Barcelona, Spain.
María Isabel González FernándezPediatric Rheumatology Unit. Hospital Universitario y Policlínico La Fe, La Fe Health Research Institute, Valencia, Spain.
Sonia Carriquí ArenasPediatric Rheumatology Department, Hospital San Joan de Déu, Barcelona, Spain.
Violeta BittermannPediatric Rheumatology Department, Hospital San Joan de Déu, Barcelona, Spain.
Carolina Estepa GuillénPediatric Rheumatology Department, Hospital San Joan de Déu, Barcelona, Spain.
Lucía Rodríguez DíezPediatric Rheumatology Department, Hospital San Joan de Déu, Barcelona, Spain.
Estíbaliz IglesiasPediatric Rheumatology Department, Hospital San Joan de Déu, Barcelona, Spain.
Miguel Marti MasanetPediatric Rheumatology Unit. Hospital Universitario y Policlínico La Fe, La Fe Health Research Institute, Valencia, Spain.
Lucía LaCruz PérezPediatric Rheumatology Unit. Hospital Universitario y Policlínico La Fe, La Fe Health Research Institute, Valencia, Spain.
Carmen PeralPfizer S.L.U, Alcobendas, Madrid, Spain.
Alfonso De LossadaPfizer S.L.U, Alcobendas, Madrid, Spain.
Mónica ValderramaPfizer S.L.U, Alcobendas, Madrid, Spain.
Noelia LlevatPfizer S.L.U, Alcobendas, Madrid, Spain.
María MontoroPfizer S.L.U, Alcobendas, Madrid, Spain. maria.montoro@pfizer.com.ORCID http://orcid.org/0000-0002-1807-7044
Jordi AntónPediatric Rheumatology Department, Hospital San Joan de Déu, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo assess the psychosocial impact of moderate-severe juvenile idiopathic arthritis (JIA) on patients and their families, among those who had been treated with at least one anti-tumor necrosis factor (anti-TNF-α), according to routine clinical practice in Spain. PATIENTS AND

methodsA 24-month observational, multicentric, cross-sectional and retrospective study was performed. Children diagnosed with JIA were enrolled at three tertiary-care Spanish hospitals. The study included children treated with biologic disease-modifying antirheumatic drugs (bDMARD) who participated in a previous study, the ITACA, and who continued follow-up in these pediatric rheumatology units. Patient health-related quality of life (HRQoL) was assessed using the Pediatric Quality of Life Inventory (PedsQL™). Caregivers completed an interview to gather information about school attendance, their children's participation in school and social activities, its impact on their jobs and social life and perceived psychosocial support. A descriptive statistical analysis of all the variables was performed. The Mann-Whitney-U test or Kruskall-Wallis H test were used to compare quantitative variables and Fisher's exact tests was used for qualitative variables. Tests were two-tailed with a significance level of 5%. The data were analyzed using SPSS V18.0 statistical software.

resultsOne hundred and seven patients were included. Overall, patients were on inactive disease or low disease activity according to JADAS-71 score and had very low functional disability according to CHAQ score. Up to 94.4% of patients were receiving drug treatment, mainly with bDMARD in monotherapy (84.5%). Based on PedsQL, patients and parents referred a high HRQoL. School Functioning PedsQL domain achieved the lowest score. Work and social impact due to the child´s disease was greater for mothers than for fathers. The understanding of the disease was lower at school than in the with family and friends' environments.

conclusionMost of the patients had a high HRQoL and had controlled disease activity, despite having a negative psychosocial impact on some of them and their families, mainly on school functioning. Children's disease seems to involve greater work and psychosocial impacts for mothers than for fathers of children affected by JIA.

Indexed as

Antirheumatic AgentsArthritis, JuvenileQuality of LifeAdolescentCaregiversChildChild, PreschoolCross-Sectional StudiesFamilyFemaleHumansMaleRetrospective StudiesSpainAntirheumatic AgentsChildrenFamilyJIAPsychosocialWork

Identifiers

PMID39593042
PMCPMC11600913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.